New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Abstract

Purpose of reviewStaphylococcus aureus is a pathogen incriminated in skin and soft tissue infections (SSTIs), with methicillinresistant S. aureus (MRSA) becoming the predominant cause and representing a significant burden to the healthcare system. The last updated Infectious Diseases Society of America (IDSA) guidelines concerning MRSA infections and SSTIs management were published in 2011 and 2014, respectively. The UK updated guidelines for MRSA infection treatment were published in 2021. Older treatment options may be associated with toxicity and require frequent dosing. There is a paucity of recent reviews on the armamentarium of new agents for MRSA SSTIs treatment. Recent findingsSince 2005, several new antibiotics received a fast-track approval by the Food and Drug Administration (FDA) for SSTI treatment. These drugs include delafloxacin, omadacycline, tedizolid, ceftaroline, dalbavancin, oritavancin and telavancin. In this manuscript, we will review the data that led to these new drugs approval and discuss their advantages and disadvantages in MRSA SSTIs management. SummaryMRSA is a major cause of SSTIs. Several novel therapies covering MRSA were FDA-approved for SSTIs. However, the current IDSA guidelines for MRSA infection and SSTIs as well as the recently published UK guidelines on MRSA treatment only consider these drugs as alternative choices or do not mention them at all. Keywordsacute bacterial skin and skin structure infections, methicillin-resistant Staphylococcus aureus, skin and soft tissue infections admissions for SSTIs was increasing by 30% from 2000 to 2004, a more recent study showed a decrease of 15.8% in MRSA-related hospitalizations between 2010 and 2014 [7,8].Historically, community-acquired MRSA (CA-MRSA) was genetically different from hospitalacquired-MRSA (HA-MRSA) and could be clinically differentiated because it was essentially causing limited to uncomplicated SSTIs [9]. However, the

Co-delivery of vancomycin, ampicillin nano-antibiotics by solid lipid nanoparticles on wound infection caused by Staphylococcus aureus: in vitro and in vivo study

“…Infection at the surgical site (SSI) is considered one of the most important complications after surgery. When infection occurs after surgery, the use of long-term antibiotics is necessary to control the infection, which increases the patient's hospitalization and increases the cost of medical care (17). Treatment of MRSA infections has become challenging due to resistance to a wide range of beta-lactam antibiotics.…”

Clinical Profile of Monomicrobial Corynebacterium Hip and Knee Periprosthetic Joint Infections

“…Several new antibiotics with good gram-positive activity were made available over the last 2 decades to treat skin and soft tissue infections [ 28 ]. These include delafloxacin, omadacycline, tedizolid, dalbavancin, telavancin, oritavancin, and eravacycline, which are available in either oral or IV formulation.…”

Vancomycin Resistance in Enterococcus and Staphylococcus aureus

“…As such, the use of modified glycopeptide derivatives such as dalbavancin, oritavancin, and telavancin, and/or combinational antibiotic therapy is typically exercised as a way to overcome AMR [ 485 ]. While there remains a limited supply of novel antibiotics in development [ 486 , 487 , 488 , 489 ], the emergence of resistance to future approved antibiotic treatment regimens is expected [ 490 ]. Although R&D pathways surrounding new-class antibiotics represent a possible path forward, these programs remain high risk, expensive, and time-consuming endeavors that many pharmaceutical companies have withdrawn from [ 9 , 491 , 492 , 493 ].…”